The interval between the original illness and the relapse is what makes the case extraordinary. Very late relapses of central nervous system germinoma, defined loosely as recurrences appearing many years after complete remission, are rare enough that standardized salvage protocols do not exist. Complicating matters further, this patient already lived with the chronic endocrine consequences of his first tumor and its treatment: central diabetes insipidus, in which the pituitary fails to release antidiuretic hormone and the kidneys excrete dilute urine uncontrollably, and panhypopituitarism, a global deficiency of pituitary hormones requiring lifelong replacement of cortisol, thyroid hormone, and other axes. Any future treatment would have to be layered onto this fragile hormonal scaffolding.

Equally notable was the anatomy of the recurrence. The new tumor sat in the optic nerve within the orbit, a location that fell outside the radiation field used to treat the original suprasellar lesion. That detail matters scientifically because it illustrates how germinoma cells can seed distant neural compartments while evading the very beams intended to eradicate them, and it underscores why long-term surveillance of survivors must extend beyond the treated volume. Imaging also raised suspicion of a hemorrhagic lesion in the right middle cerebellar peduncle, though the team could not obtain a biopsy and cerebral angiography revealed no detectable vascular abnormality, leaving that finding radiographically suspicious but pathologically unconfirmed.

To achieve cure, the oncologists selected a salvage regimen of ifosfamide, cisplatin, and etoposide, the ICE combination that is a workhorse of germ cell tumor therapy. Cisplatin is among the most nephrotoxic drugs in clinical use; it injures the proximal renal tubules, which are responsible for reabsorbing the bulk of filtered sodium, glucose, and other solutes. Ifosfamide adds its own tubular toxicity, and together the two agents can push the kidney into a state where it literally wastes salt into the urine. In a patient whose antidiuretic hormone axis was already absent, the stage was set for a perfect storm of sodium and water derangement.

That storm arrived during the chemotherapy course as symptomatic grade 4 hypotonic hyponatremia, the most severe category of sodium depletion. The patient’s serum sodium fell to 118.4 milliequivalents per liter, with a serum osmolality of 236 milliosmoles per kilogram, values low enough to risk cerebral edema, seizures, and death. Severe hyponatremia of this kind is a medical emergency, but treating it is deceptively complex, because the correction itself must be gradual; raising sodium too quickly can precipitate osmotic demyelination syndrome, a devastating injury to the brainstem. The team responded with hypertonic saline, isotonic fluids, oral salt supplementation, and serial measurement of both serum and urine chemistries.

The most instructive data came from the rechallenge. When the same drugs were given again, the clinical team recorded urine output rising from 1.40 liters per day at the start of the second cycle to 4.25 liters per day by day three and a remarkable 9.75 liters per day by day four, accompanied by high spot urinary sodium concentrations. In other words, the kidneys were dumping enormous volumes of sodium-rich urine precisely when the chemotherapy was on board. This temporal link between drug exposure and massive salt loss is the kind of physiological fingerprint that clinicians use to distinguish drug-induced renal salt wasting from other causes of hyponatremia.

Here, however, the authors are careful about what the evidence can and cannot prove. Because oral intake, intravenous fluid volumes, net fluid balance, objective volume status, and fractional urate excretion were unavailable, they classified the episode as a chemotherapy-associated mixed sodium and water disturbance with a suspected salt-wasting component rather than confirmed renal salt wasting. This distinction is more than academic hair-splitting. True renal salt wasting is treated with aggressive sodium repletion, whereas the syndrome of inappropriate antidiuretic hormone secretion, which can also accompany chemotherapy, calls for fluid restriction. In a patient with central diabetes insipidus on desmopressin, a synthetic antidiuretic hormone, the picture becomes a three-way puzzle: too little antidiuretic hormone by nature, possible inappropriate secretion masked by replacement therapy, and drug-driven tubular salt loss all competing in the same body.

The recurrent toxicity ultimately forced a change in strategy. Cisplatin and ifosfamide were discontinued, and the regimen was switched to carboplatin plus etoposide, a platinum pairing that trades some of cisplatin’s potency for a gentler renal profile. The high-output sodium-wasting pattern attenuated on the new regimen, although grade 3 hyponatremia persisted, indicating that the kidneys remained vulnerable even after the most offending agents were withdrawn. Crucially, the supportive framework of hypertonic saline, isotonic fluids, oral salt, and close laboratory monitoring allowed the team to complete the full curative-intent chemotherapy course and proceed to craniospinal irradiation without abandoning the goal of cure.

The outcome validates that persistence. At the one-year imaging assessment, the patient maintained a complete response, meaning no evidence of active tumor could be detected. For a young man who had already survived one brain germinoma in childhood and then faced a second, out-of-field recurrence a decade later, the achievement of durable remission despite life-threatening metabolic complications is a genuinely encouraging result. It demonstrates that severe electrolyte toxicity, while frightening, can be managed intensively enough to keep a curative treatment plan on track.

The broader lessons of this case-based review extend well beyond a single patient. Survivors of central nervous system germinoma need decades of surveillance, because very late relapses can appear in unexpected, previously unirradiated sites, and chronic pituitary dysfunction reshapes how the body handles every future physiological stress. For oncologists, the case is a warning that platinum and alkylating-agent salvage therapy in patients with pre-existing diabetes insipidus demands obsessive attention to urine output, urinary sodium, and serum osmolality, with early escalation of salt repletion and willingness to modify the regimen. For researchers, it highlights how much remains unknown about the intersection of tubular drug toxicity and hypothalamic-pituitary disease, and how careful documentation of fluid balance in future cases could turn suspicion of renal salt wasting into proof. The report, published open access, adds a valuable data point to the sparse literature on a complication that is easy to miss and dangerous to ignore.

Subject of Research: Chemotherapy-associated hyponatremia during salvage therapy for very late relapse of central nervous system germinoma

Article Title: Chemotherapy-associated hyponatremia during curative-intent salvage therapy for very late relapse of central nervous system germinoma: a case-based review

Article References: Ohkuma, R., Tsurui, T., Ishiguro, T., Ikeda, G., Shimokawa, M., Ariizumi, H., Suzuki, R., Osaka, N., Shiraga, Y., Shimura, K., Hara, H., Nakai, T., Inaba, T., Yamashita, M., Kawamori, S., Sato, A., Shiozawa, E., Tanioka, D., Kubota, Y., … Horiike, A. (2026). Chemotherapy-associated hyponatremia during curative-intent salvage therapy for very late relapse of central nervous system germinoma: a case-based review. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06637-z

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06637-z

Keywords: central nervous system germinoma, hyponatremia, chemotherapy, renal salt wasting, central diabetes insipidus, salvage therapy, optic nerve relapse, cisplatin, ifosfamide, carboplatin, etoposide, late relapse

The research team, led by Shengbo Cai of the Fifth Hospital of Xiamen and including colleagues from Peking University Shenzhen Hospital, reviewed the clinical records of 519 children hospitalized with symptomatic COVID-19 between December 2022 and December 2025. This three-year window allowed the investigators to compare two distinct epidemiological eras: a calendar period in which Omicron BA.5 and its close descendants predominated, and a subsequent post-BA.5 period characterized by later viral variants. The cohort was strikingly young. Infants and toddlers accounted for 345 of the 519 admissions, or 66.4 percent, underscoring that the youngest children continue to bear a disproportionate share of pediatric COVID-19 hospitalizations even years into the pandemic.

When the researchers classified disease severity, they found that 192 patients, or 37.0 percent, had mild disease, 227 patients, or 43.7 percent, had moderate disease, and 100 patients, or 19.3 percent, fell into the severe or critical category. Notably, every child in the cohort improved or achieved clinical recovery, a reassuring outcome that reflects both the inherent resilience of young patients and the quality of supportive care available at the study center. Nevertheless, nearly one in five hospitalized children required classification as severe or critical, a proportion high enough to justify a careful search for early warning signs that could help clinicians triage and monitor admissions.

The comparison between the two calendar periods revealed a consistent pattern of attenuation over time. Children admitted during the post-BA.5 period experienced a lower proportion of severe and critical disease, needed supplemental oxygen less often, spent fewer days in the hospital as measured by the median length of stay, and suffered fewer complications overall. All of these differences reached statistical significance, with P values below 0.05. The picture was not uniformly favorable in the later period, however. Neurological symptoms were actually more frequent during the BA.5-predominant calendar period, while the rate of viral co-detection, meaning the simultaneous presence of other respiratory pathogens alongside SARS-CoV-2, was lower during that same period. These shifting patterns illustrate how the clinical phenotype of pediatric COVID-19 is not static but evolves in tandem with the viral population.

To identify factors independently associated with severe and critical disease, the team turned to multivariable logistic regression, the standard statistical tool for isolating the effect of each candidate predictor while accounting for the others. In the primary analysis, three factors emerged: the presence of neurological symptoms, admission during the BA.5-predominant calendar period, and young age. On its face, this result seemed to suggest that children presenting with seizures, encephalopathy, or other neurological manifestations were at markedly elevated risk of progressing to severe or critical illness, and that infants and toddlers faced greater danger than older children.

But the investigators did not stop there, and it is their methodological rigor that elevates this study above many similar analyses. Recognizing two subtle statistical pitfalls, definitional circularity and quasi-complete separation, they repeated the analysis using Firth penalized regression, a technique that applies a penalty term to stabilize estimates when data are sparse or when a predictor almost perfectly separates the outcome groups. Definitional circularity arises when a symptom is itself part of the definition of severe disease, guaranteeing a spurious association; quasi-complete separation occurs when every patient with a certain feature shares the same outcome, producing extreme and unreliable odds ratios. The sensitivity analysis exposed exactly these problems. The extreme estimate for neurological symptoms was driven by circularity, and the associations involving the calendar periods and age groups proved unstable across different model specifications, fluctuating depending on how the variables were defined and adjusted.

What survived this gauntlet of sensitivity testing were two laboratory parameters: hyponatremia, an abnormally low concentration of sodium in the blood, and an elevated neutrophil count. Unlike the clinical and demographic variables, these two markers remained consistently and independently associated with severe and critical disease in both the primary multivariable regression and the Firth penalized sensitivity analyses. This robustness matters enormously for clinical practice, because a predictor that holds up across statistical approaches is far more likely to be genuine and reproducible than one that appears and disappears depending on model assumptions.

The biological plausibility of both markers lends further weight to the finding. Hyponatremia is a well-recognized complication of respiratory infections in children and can arise through several mechanisms, including the syndrome of inappropriate secretion of antidiuretic hormone, in which excess ADH causes water retention and dilution of serum sodium. Inflammatory cytokines such as interleukin-6, which surge in severe COVID-19, can stimulate ADH release, linking low sodium to the intensity of the host immune response. An elevated neutrophil count, meanwhile, is a classic hallmark of bacterial coinfection, intense systemic inflammation, or tissue damage, all of which correlate with worse outcomes in respiratory viral disease. In this sense, the two surviving predictors may be capturing the same underlying phenomenon: a hyperinflammatory host response that drives both electrolyte disturbance and granulocyte production.

The authors draw a careful and clinically useful distinction in their conclusions. Neurological symptoms, they argue, should be regarded as clinical red flags rather than independent statistical predictors. A child who presents with a seizure or altered consciousness warrants close observation and urgent evaluation regardless of what a regression model says, but the association between such symptoms and severe disease is partly an artifact of how severity is defined. By contrast, routine monitoring of serum sodium levels may be considered a practical addition to the care of hospitalized children with COVID-19, since a falling sodium concentration could serve as an early, objective warning of deterioration. Neutrophil counts are already measured routinely in most hospitals, making both of the validated markers essentially free to track once a child is admitted.

The study has limitations inherent to its design. As a single-center retrospective review conducted at the Fifth Hospital of Xiamen, its findings may not generalize to populations with different demographic profiles, vaccination coverage, or access to care, and retrospective designs cannot exclude residual confounding. The stability of the two laboratory associations across sensitivity analyses, however, gives the results a credibility that many risk-factor studies lack, and the honest reporting of unstable estimates for age, calendar period, and neurological symptoms is a model of statistical transparency. As SARS-CoV-2 continues to mutate and pediatric COVID-19 continues to evolve, studies like this one, which combine large observational cohorts with rigorous sensitivity analysis, will remain essential for helping clinicians distinguish the children who can be safely managed with routine supportive care from those who need intensified monitoring before their condition spirals. For now, the message for pediatricians is refreshingly concrete: watch the sodium, watch the neutrophils, and treat neurological symptoms as urgent warning signs rather than statistical curiosities.

Subject of Research: Risk factors for severe and critical COVID-19 in hospitalized children during the Omicron BA.5-predominant and post-BA.5 periods

Article Title: Severe and critical COVID-19 in children during the Omicron BA.5-predominant and post-BA.5 calendar periods: clinical characteristics and risk factors

Article References: Severe and critical COVID-19 in children during the Omicron BA.5-predominant and post-BA.5 calendar periods: clinical characteristics and risk factors. (n.d.). https://doi.org/10.1186/s12887-026-07751-0

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07751-0

Keywords: COVID-19, children, SARS-CoV-2, Omicron BA.5, hyponatremia, neutrophils, pediatrics, risk factors, neurological symptoms, hospitalization, logistic regression, BMC Pediatrics

Second-generation antipsychotics, sometimes called atypical antipsychotics, were introduced in part because they promised a more favorable side-effect profile than the older first-generation drugs, which were notorious for causing movement disorders. Previous research had hinted that the second-generation class as a whole might carry a lower risk of hyponatremia than the first-generation agents. What remained unclear, however, was whether the risk differed meaningfully between individual drugs within the class. This distinction matters enormously in clinical practice. If all second-generation antipsychotics carried the same hyponatremia risk, clinicians could choose among them based on other considerations. But if the risk varies from one molecule to the next, that variation could become a decisive factor when prescribing for patients who are already vulnerable to sodium disturbances, such as older adults, people taking other medications that affect sodium levels, or those with underlying medical conditions.

Addressing this question, a research team led by Associate Professor Masakazu Hatano of the Department of Pharmacotherapeutics and Informatics at Fujita Health University School of Medicine in Japan, together with Dr. Takenao Koseki, Dr. Takeo Saito, and Dr. Shigeki Yamada, all affiliated with the same institution, carried out a two-stage comparative safety study. Their strategy combined two very different types of data, each with distinct strengths and weaknesses, to arrive at conclusions more robust than either source could provide alone. Hyponatremia is a recognized safety concern associated with antipsychotic use, but as Dr. Hatano explained, comparative evidence among individual second-generation antipsychotics has remained limited. The team therefore adopted a two-stage approach, first using a spontaneous reporting system to generate hypotheses about hyponatremia risk among individual drugs, and then using a claims database to evaluate the associations suggested by the first analysis.

The hypothesis-generating stage drew on the US Food and Drug Administration Adverse Event Reporting System, a vast pharmacovigilance repository that collects reports of suspected side effects from manufacturers, healthcare professionals, and patients. The researchers examined reports spanning from the fourth quarter of 1997 to the third quarter of 2023, an enormous window covering more than a quarter century of clinical use. In total, the analysis included 17,805,418 reports, of which 458,745 involved second-generation antipsychotic monotherapy, meaning patients taking a single antipsychotic rather than a combination. Using a statistical technique known as disproportionality analysis, which compares how often a given adverse event is reported for one drug relative to others, the team calculated reporting odds ratios for hyponatremia with olanzapine as the reference drug. Several antipsychotics showed lower reporting odds than olanzapine, and brexpiprazole and lurasidone showed the lowest reporting odds of all.

However, the researchers were careful to emphasize that these findings could only be considered hypothesis-generating rather than definitive. Spontaneous reporting systems suffer from a fundamental limitation: they provide no denominator information. In other words, while the database records how many adverse event reports mention a particular drug, it does not record how many people in total took that drug. Without knowing the size of the exposed population, it is impossible to calculate actual incidence or absolute risk. Reporting is also vulnerable to biases, including heightened attention to certain drugs, differences in how adverse events are recognized and attributed, and the passage of time as drugs gain or lose market share. A drug that is newly marketed or heavily scrutinized may generate more reports simply because clinicians are watching it more closely, not because it is genuinely more dangerous.

This is precisely why the second stage of the study was essential. The researchers turned to a Japanese hospital-based claims database covering April 2008 to April 2024, which allowed them to observe real patients over time rather than relying on voluntary reports. From this database, they identified 55,394 patients who were newly prescribed antipsychotics, had no recent antipsychotic use, and had no existing hyponatremia, ensuring that the analysis captured new-onset events rather than pre-existing conditions. Each patient was followed for up to 180 days after starting treatment, a window long enough to capture events plausibly related to the medication while limiting the influence of unrelated changes over time. During the follow-up period, hyponatremia occurred in 366 patients, representing 0.7 percent of the cohort, a figure that provides the kind of absolute risk context that spontaneous reporting data can never supply.

The critical analytical challenge in observational studies of this kind is confounding. Patients are not randomly assigned to antipsychotics; clinicians choose drugs based on patient characteristics, illness severity, prior treatment history, and anticipated tolerability. These same characteristics may independently influence hyponatremia risk. To address this, the researchers used statistical weighting methods to account for differences in baseline characteristics and other factors influencing risk, effectively creating balanced comparison groups. After adjustment, one finding stood out clearly: aripiprazole was associated with a significantly lower risk of hyponatremia than olanzapine. The other antipsychotics examined did not show significant differences compared with olanzapine once adjustment was applied, a notable contrast with the unadjusted signals from the reporting database, where several drugs had appeared more favorable.

These findings suggest that the risk of hyponatremia may differ among individual second-generation antipsychotics, Dr. Hatano clarified, adding that aripiprazole was associated with a lower risk than olanzapine in the adjusted analysis, which may help inform antipsychotic selection for patients at higher risk of hyponatremia. The result is pharmacologically plausible. Aripiprazole is a partial dopamine agonist with a distinctive receptor profile that sets it apart from most other second-generation agents, and olanzapine is known for broader receptor binding and a heavier metabolic and sedative burden. While the study was not designed to establish mechanism, the divergence between these two widely used drugs underscores that the second-generation label conceals real pharmacological heterogeneity with potential clinical consequences.

The researchers were candid about the limitations of their work. The study was observational, meaning it could identify associations but not prove causation. Residual confounding, the possibility that unmeasured differences between patient groups influenced the results, cannot be excluded, and differences in how hyponatremia was detected across treatment groups may also have shaped the findings. Laboratory monitoring practices, for example, may differ depending on the drug prescribed and the patient’s perceived risk, which could bias event ascertainment. The Japanese setting of the claims analysis raises questions about generalizability to other populations, and the 180-day follow-up window may not capture risks emerging over longer treatment periods. The authors also disclosed financial relationships with numerous pharmaceutical companies, which are documented in the published conflict of interest statement.

Despite these caveats, the study represents a valuable methodological template for drug safety research. By combining the breadth of a pharmacovigilance database with the clinical realism of claims data, the researchers generated and then tested hypotheses in a way that neither source could accomplish alone, providing complementary evidence for comparing drug safety while transparently acknowledging the limitations of each approach. For clinicians, the practical message is that hyponatremia risk deserves consideration when selecting among second-generation antipsychotics, particularly for patients with additional risk factors such as advanced age, thiazide diuretic use, or pre-existing sodium disturbances. For researchers, the findings highlight the need for further studies to elucidate the associations between individual second-generation antipsychotics and hyponatremia, ideally with designs capable of confirming mechanism and quantifying absolute risk across diverse populations. As antipsychotic prescribing continues to expand worldwide, studies of this kind bring precision to a class of drugs too often treated as interchangeable, moving psychiatric pharmacotherapy closer to genuinely individualized care.

Subject of Research: Comparative risk of hyponatremia among second-generation antipsychotics

Article Title: Hyponatremia risk may differ across second-generation antipsychotics

Article References: Hyponatremia risk may differ across second-generation antipsychotics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hyponatremia, second-generation antipsychotics, aripiprazole, olanzapine, pharmacovigilance, FAERS, claims database, drug safety, schizophrenia, bipolar disorder, JAMA Network Open, observational study

The research team, led by Takuya Nishino of the Department of Health Policy and Management at Nippon Medical School, designed the study around a methodological device known as landmark analysis. Instead of asking a single question about the entire hospital stay, the investigators froze time at two specific points, hospital day 3 and hospital day 7, and examined what had changed in each patient up to those moments. They then tracked whether the patient experienced a first documented in-hospital fall within the following 30 days. This design matters because fall risk is not static. A patient who walks in with intact mobility and normal blood values may, by the end of the first week, be a very different physiological creature than the one who was admitted, and a risk score calculated at the front door cannot see that transformation.

The scale of the dataset gives the conclusions unusual weight. Of 112,103 eligible patients aged 65 years or older, 83,297 remained in the day-3 cohort and 61,071 in the day-7 cohort after the researchers applied their inclusion criteria. Patients ranged in age from 65 to 106 years, and roughly 40 percent of each cohort was female. Because the study drew on electronic health records and administrative data from two tertiary centers, the population reflects the everyday complexity of acute hospital medicine, with all its comorbidities, medications, and incomplete documentation. Missing data, an unavoidable feature of real-world records, were handled with multiple imputation by chained equations, a statistical technique that fills gaps by modeling each incomplete variable conditionally on the others, and the results held up across sensitivity analyses designed to probe the robustness of the associations.

The functional signal centered on transfer ability, the capacity to move between a bed, a chair, and a standing position, which is one of the most fundamental building blocks of independence. The researchers classified each patient’s functional trajectory by comparing transfer status at admission with transfer status at the landmark day. What they found was strikingly consistent: patients whose transfer impairment persisted or worsened by hospital day 3 faced a higher risk of falling in the subsequent month, and the same held true at day 7. Acute functional decline, meaning a deterioration between admission and the landmark, was associated with elevated fall risk at day 7 but not at day 3. That asymmetry is itself informative. It suggests that the earliest days of a stay may not capture decline that has not yet had time to emerge, while a full week of observation reveals patients on a downward functional slope who are precisely the ones most likely to fall.

The physiological signals were equally specific. Declines in hemoglobin, the oxygen-carrying pigment of red blood cells, were independently associated with higher fall risk at both landmarks, and so were drops in serum sodium, the principal electrolyte governing the tonicity of extracellular fluid. Changes in serum albumin, a protein often used as a marker of nutritional status and inflammation, showed no independent association with falls. The selectivity is important. It indicates that the relationship is not a generic marker of being sick, but something closer to a mechanistic story about how the body maintains the conditions required for safe movement.

Both of the implicated parameters have plausible biological routes to the floor. Anemia reduces oxygen delivery to muscles and the brain, and prior research has linked low hemoglobin to declines in physical performance and to dynapenia, the age-related loss of muscle strength. A patient whose hemoglobin falls during hospitalization, whether through blood loss, hemodilution from intravenous fluids, or underlying illness, may experience fatigue, weakness, and orthostatic lightheadedness, each of which undermines the delicate neuromuscular coordination that transfers and walking demand. Hyponatremia has an even more direct neurological pedigree. Sodium is essential for the electrochemical signaling of neurons, and even mild chronic hyponatremia has been associated in earlier studies with unsteadiness, attention deficits, gait disturbance, and increased rates of falls and fractures. A falling sodium level in an older inpatient may therefore quietly erode the cognitive and motor precision that prevents a misstep, long before anyone notices a problem.

Why albumin failed to make the cut is a question the authors address through the lens of prior literature. Serum albumin is a notoriously slippery indicator, influenced by inflammation, hydration, liver function, and capillary leakage as much as by nutrition, and its trajectory during a short hospital stay may simply move too slowly or too noisily to track the fast-changing physiology that precedes a fall. Hemoglobin and sodium, by contrast, can shift meaningfully within days in response to bleeding, fluid shifts, diuretics, and the stress response of acute illness. In that sense, the study’s negative finding for albumin is as useful as its positive ones, because it tells clinicians which laboratory trends are worth scheduling repeated checks for and which are not, at least for the specific purpose of fall prediction.

The practical implications reach into one of the most stubborn problems in hospital safety. Fall prevention programs have proliferated for decades, yet systematic reviews and meta-analyses, including work cited by the authors, show that their effects are often modest, and that most conventional risk assessment tools are completed once, at admission, and then filed away. The new study argues for a rhythm rather than a snapshot: scheduled reassessment of transfer ability and targeted laboratory parameters on hospital days 3 and 7, complementing the admission evaluation. Such a rhythm would catch evolving vulnerability, the patient who was low-risk on arrival but is becoming high-risk as anemia deepens or sodium drifts down, and it would give nursing staff a time-sensitive trigger to intensify interventions, whether that means closer supervision during transfers, bed and chair alarms, mobility assistance, or a medication review. The authors frame this as a way to identify older patients who require intensified fall-prevention measures, and the landmark structure of their analysis maps almost directly onto a feasible clinical workflow.

The study’s limitations are the familiar ones of retrospective design. The researchers could observe associations, not prove causation, and unmeasured factors, from sedating medications to delirium to staffing levels on a given ward, may shape both the laboratory trajectories and the fall events. Falls documented in administrative data may also undercount the true total, since not every fall is recorded. The data came from two Japanese tertiary hospitals, and the datasets, which contain sensitive individual-level clinical information, are not publicly available, which limits independent replication, although the multicenter design and the sheer sample size lend credibility to the central patterns. The work was supported by the Japan Society for the Promotion of Science through a KAKENHI grant, and the team included specialists spanning health policy, cardiovascular medicine, medical safety, nursing, and anesthesiology, a breadth that reflects the multidisciplinary nature of the problem itself.

What makes the study resonate beyond geriatrics is its conceptual shift. Falls have long been treated as a geriatric syndrome, a multifactorial failure at the intersection of aging bodies and hazardous environments, and the field’s own literature acknowledges that hospitalization itself is a driver of disability, a phenomenon memorably described in the medical literature as patients who were probably able to ambulate but whose capacity quietly evaporated during a stay. By showing that the seeds of a fall are visible in measurable trajectories within the first week, the Japanese team offers a way to intervene before the fall rather than after it. The message for hospitals is deceptively simple: check the blood, check the transfer, and check again on day 3 and day 7. The message for science is broader still, that the most dangerous changes in aging patients may be the ones that unfold slowly, in routine laboratory values and bedside observations, waiting for someone to look twice.

Subject of Research: Early in-hospital functional and physiological changes as predictors of fall risk in hospitalized older adults

Article Title: Association between early in-hospital physiological and functional changes and fall risk in older adults: a retrospective multicenter cohort study

Article References: Nishino, T., Kubota, Y., Miyagi, Y., Tanabe, N., Yamaguchi, F., Ito, H., Soh, S., Yano, A., Mizuno, M., Kim, C., Ishii, Y., & Asai, K. (2026). Association between early in-hospital physiological and functional changes and fall risk in older adults: a retrospective multicenter cohort study. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01622-8

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01622-8

Keywords: falls, older adults, hospitalization, functional decline, hemoglobin, hyponatremia, serum albumin, landmark analysis, geriatrics, patient safety, cohort study, fall prevention

The study, published in European Geriatric Medicine by a team led by Marinus Fislage of Charité – University Medical Center Berlin, examined 618 patients aged 65 and older who were scheduled for elective surgery expected to last at least 60 minutes. None of the participants had dementia, and all had routinely obtained preoperative sodium measurements available. Using standard clinical thresholds, the researchers classified 31 patients, or 5.0 percent of the cohort, as hyponatremic, with sodium values ranging from 125 to 134 mmol/L, and 16 patients, or 2.6 percent, as hypernatremic, with values between 146 and 150 mmol/L. In total, only 7.5 percent of these older surgical patients carried any sodium abnormality before their operation, a figure that itself is informative about how uncommon clinically relevant dysnatremia is in an elective surgical population.

The raw numbers, however, were striking. Patients with abnormal sodium levels fared dramatically worse across every outcome the investigators tracked. Postoperative delirium, an acute and often devastating disturbance of attention and cognition that affects roughly one in five older surgical patients, occurred in 38.3 percent of the dysnatremia group compared with 20.8 percent of those with normal sodium. In-hospital mortality was more than tenfold higher, at 17.0 percent versus 1.6 percent. By 90 days after surgery, 27.7 percent of patients with abnormal sodium had died, compared with just 2.8 percent of the normonatremic group. Severe complications, graded as Clavien-Dindo class II or higher, affected 65.2 percent of the dysnatremia group against 38.4 percent of the rest. On the surface, these are the kinds of associations that make headlines and prompt calls for routine sodium-targeted interventions.

But the BioCog team asked a more demanding question than whether abnormal sodium and bad outcomes travel together. They wanted to know whether adding sodium to prediction models that already contain established clinical risk factors actually improves the models’ ability to distinguish which individual patients will suffer delirium, complications, or death. This distinction matters enormously in clinical practice. A variable can be strongly associated with an outcome in aggregate yet add almost nothing to individual-level prediction if its information is already captured by other variables, or if the abnormality is simply too rare to move the needle for the population as a whole. Confusing these two properties, association and incremental predictive value, is one of the most common pitfalls in biomarker research, and the study was explicitly designed to avoid it.

The methodological machinery the researchers deployed reflects that ambition. For each outcome, they built multivariable prediction models incorporating established clinical risk factors and then measured what happened when abnormal sodium was added. Discrimination, the model’s ability to separate patients who experience an outcome from those who do not, was quantified using the area under the receiver-operating characteristic curve, or AUROC, with bootstrap correction to guard against over-optimism. Calibration, whether predicted probabilities match observed event rates, was assessed with Brier scores, which penalize both discrimination failures and miscalibration. Postoperative delirium, the primary outcome, was assessed not by impression but with a battery of four validated diagnostic tests, a rigor that distinguishes BioCog from many chart-based delirium studies.

The verdict on delirium and complications was sobering. Adding dysnatremia to the delirium model nudged the AUROC from 0.71 to 0.72, but the bootstrap-corrected difference was a mere 0.0045, with a 95 percent confidence interval stretching from −0.0027 to 0.0199, a range that includes zero. For postoperative complications, the picture was nearly identical, with an optimism-corrected gain of 0.004 and a confidence interval of −0.0011 to 0.0124. Brier scores showed only marginal differences for these outcomes as well. In plain terms, knowing a patient’s sodium status before surgery tells a clinician almost nothing about that individual’s risk of delirium or complications beyond what age, comorbidity, type of surgery, and other established factors already reveal. The 38 percent delirium rate among dysnatremic patients is alarming, but with only 47 such patients in the cohort, the signal is too sparse and too entangled with other risk markers to sharpen anyone’s individual forecast.

Mortality told a subtler story. For in-hospital death, incorporating dysnatremia raised the optimism-corrected AUROC from 0.864 to 0.889, a difference of 0.023 with a confidence interval of 0.0046 to 0.0435 that excludes zero. For 90-day mortality, the bootstrap-validated C-index climbed from 0.91 to 0.93, a median increase of 0.021 with a confidence interval of 0.001 to 0.057. These are small but statistically reliable gains, and the authors are careful to frame them as exploratory findings that warrant further study rather than as a mandate for clinical change. Even here, the Brier scores barely moved, suggesting that while sodium helps rank patients by mortality risk, it does little to improve the accuracy of the predicted probabilities themselves. A gain of roughly two hundredths of a C-index, in the framework of decision-analytic literature on new markers, rarely justifies changes in care pathways on its own.

Why does a marker so visibly linked to death and delirium fail as a predictor? The answer lies in biology and in arithmetic. Dysnatremia in older adults is rarely an isolated electrolyte quirk; it is typically the downstream consequence of heart failure, kidney disease, malignancy, diuretic use, or general frailty, all of which are already captured by the covariates in a well-constructed prediction model. Sodium, in this sense, behaves as a messenger summarizing information the model already possesses. Meanwhile, its rarity, affecting fewer than one in twelve patients in this elective cohort, mathematically caps how much any population-level discrimination metric can improve. Prior large studies, including an analysis of major surgical populations by Cecconi and colleagues and a Danish cohort of nearly 280,000 acutely hospitalized patients, have consistently shown that even mild hyponatremia carries elevated mortality risk, yet the BioCog results suggest that in elective surgery the marker’s predictive ceiling is low precisely because the sickest patients are filtered out before they reach the operating room.

The clinical implications cut in two directions. On one hand, the study argues against investing heavily in sodium-based risk stratification tools for delirium prevention or complication prediction in older elective surgical patients; existing algorithms, including one recently developed and internally validated from the same BioCog cohort and published in the British Journal of Anaesthesia, already perform well without it. On the other hand, the strong associations with mortality serve as a reminder that a preoperative sodium value outside the 135 to 145 mmol/L range should never be dismissed as an incidental finding. It may not refine a risk calculator, but it flags a patient whose physiology is already compromised, prompting clinicians to consider whether the underlying cause, whether medication-related, endocrine, or organ-specific, can be identified and corrected before surgery. Trials of perioperative fluid management and prehabilitation programs, both active areas of research, may eventually determine whether intervening on modifiable contributors to dysnatremia can convert this marker of risk into a target of therapy.

For the growing field of perioperative medicine, the BioCog analysis offers a methodological template as much as a clinical message. By formally quantifying incremental predictive value with bootstrap-corrected discrimination metrics and Brier scores, rather than resting on relative risks alone, the researchers demonstrate how the surgical community should evaluate any candidate biomarker, from inflammatory panels to genetic signatures, before it earns a place in preoperative workflows. The study was conducted under the EU-funded BioCog project, registered as NCT02265263, and approved by the local ethics committee with written informed consent from all participants. As populations age and surgical volumes rise, the pressure to predict, and prevent, postoperative delirium and death will only intensify. This study tempers the enthusiasm for one tempting candidate while modeling the discipline required to find predictors that genuinely work.

Subject of Research: Preoperative serum sodium abnormalities and their association with and predictive value for adverse postoperative outcomes in older surgical patients

Article Title: Preoperative sodium abnormalities and adverse postoperative outcomes in older surgical patients: association and incremental predictive value in the BioCog cohort

Article References: Fislage, M., Feinkohl, I., Lammers-Lietz, F., Pischon, T., Winterer, G., Spies, C. D., Borchers, F., Zacharias, N., the BioCog Consortium, Wolf, A., Müller, A., Hadzidiakos, D., Yürek, F., Lachmann, G., Ofosu, K., Heinrich, M., Mörgeli, R., Gallinat, J., Kühn, S., … Fillmer, A. (2026). Preoperative sodium abnormalities and adverse postoperative outcomes in older surgical patients: association and incremental predictive value in the BioCog cohort. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01610-y

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01610-y

Keywords: preoperative sodium, hyponatremia, hypernatremia, postoperative delirium, postoperative complications, mortality, older surgical patients, BioCog cohort, risk prediction, perioperative medicine, geriatric surgery, electrolyte disorders

That apparent normality did not last. During his four-week admission he suffered several further episodes of transient hypothermia accompanied by hypertension and sweating, each resolving spontaneously. Over the following four years he was admitted more than a dozen times with the same constellation of symptoms: hypothermia plunging as low as 28 degrees Celsius, profuse diaphoresis, blood pressure disturbance that swung between severe hypertension and profound hypotension, and symptomatic hyponatremia with sodium levels between 119 and 132 mmol/L. On every occasion, repeat testing found no evidence of infection or endocrine disease. This pattern of periodic hypothermia, autonomic instability and low sodium pushed the clinical team toward an entirely different explanation: a thermoregulatory disorder originating in the central nervous system. When the authors re-examined his prior brain imaging, they found something the original report had missed, an abnormality of the corpus callosum together with a cavum veli interpositi, a fluid-filled structure that can accompany callosal malformations.

Those findings were supportive of a diagnosis of Shapiro syndrome, an extraordinarily rare condition first described in 1969 by Shapiro, Williams and Plum in two patients who presented with spontaneous episodic hypothermia and hyperhidrosis alongside radiographic evidence of agenesis of the corpus callosum. The corpus callosum is the thick bundle of nerve fibres connecting the brain’s two hemispheres, and its absence or malformation is the structural hallmark of the syndrome. Since the original description, the recognised phenotype has expanded to include other autonomic disturbances such as hypertension or hypotension, altered consciousness and metabolic derangement. Of the approximately 60 cases reported in the literature, about half had no evidence of callosal dysgenesis at all; these are considered a variant of the syndrome, sometimes called episodic spontaneous hypothermia, and they tend to affect older patients.

Understanding why such a syndrome can exist requires understanding how tightly the human body normally controls its temperature. The evolution of mammals from aquatic to terrestrial life posed a serious thermoregulatory challenge, because land temperatures vary far more than water temperatures. That pressure drove a transition from poikilothermy, in which body temperature drifts with the environment, to homeothermy, the ability to hold internal temperature within a narrow set range. Holding a high, stable temperature maximises enzymatic activity, speeds neural processing and improves healing. Endothermy, the generation of internal heat, gave early mammals a survival edge over ectothermic dinosaurs, which depended on external heat sources, were inactive at night, were more vulnerable to seasonal change and were in some cases restricted to particular latitudes.

In humans, the hypothalamus acts as the thermostat. The pre-optic area of the anterior hypothalamus is chiefly responsible for temperature control, integrating thermal signals arriving from skin and visceral thermoreceptors with direct measurements of hypothalamic temperature. Within this region, distinct populations of neurons perform complementary roles. Warm-sensing neurons increase their activity in response to heat and receive excitatory input from peripheral warm receptors; when they fire, they trigger heat-loss mechanisms such as sweating and peripheral vasodilation. Cold-sensing neurons make up less than 5 percent of the pre-optic population and are normally held in check by tonic inhibition from warm-sensing neurons, balanced against tonic excitation from temperature-insensitive neurons. When that inhibition is lifted, cold-defence mechanisms activate: shivering and non-shivering thermogenesis, peripheral vasoconstriction, activation of brown fat through sympathetic excitation, hypothalamic-pituitary stimulation of thyroxine production to raise basal metabolic rate, and even behavioural responses like huddling. Infection complicates this picture because endogenous pyrogens suppress warm-sensing neurons, raising the set point and producing fever.

Hypothermia itself is defined as a core temperature below 35 degrees Celsius and is graded as mild, between 32 and 35 degrees, moderate, between 28 and 32 degrees, or severe, below 28 degrees. The physiological consequences scale with severity. At the cellular level, cold drives water crystallisation, membrane disruption and protein changes, while secondary ischaemic injury follows vasoconstriction, endothelial damage and thrombosis. Mild hypothermia typically produces a catecholamine surge with tachycardia and hypertension, which may explain the striking blood pressure of 207/176 mmHg in the case described here. As temperature falls further, cardiovascular function degrades into progressive bradycardia and hypotension. Cerebral metabolic rate drops by roughly 6 percent for every 1-degree Celsius decline, producing confusion, behavioural change, ataxia and progressive obtundation. Respiratory drive is depressed, causing respiratory acidosis, while cold diuresis, impaired renal tubular function and occasional shivering-induced rhabdomyolysis disturb electrolytes, a mechanism relevant to the patient’s recurrent hyponatremia. Coagulopathy from platelet and clotting-factor dysfunction is also common.

Because so many conditions can lower body temperature, clinicians must work through a broad differential. Exogenous hypothermia from environmental exposure is compounded by age, intoxication, homelessness, low body fat and immobility. Endogenous causes include sepsis, especially gram-negative bacteraemia, hypovolaemic shock, hypoglycaemia, diabetic ketoacidosis, uremia and hepatic encephalopathy, and endocrinopathies such as hypothyroidism, adrenal failure and hypopituitarism. Drugs matter too: alcohol, opioids, barbiturates and phenothiazines impair thermal perception and cause vasodilation, while at the opposite extreme, neuroleptic malignant syndrome, serotonin syndrome and malignant hyperthermia produce dangerous overheating. Neurological causes form their own category. Peripheral neuropathies rarely cause overt thermoregulatory failure except in rare genetic disorders such as congenital insensitivity to pain with anhidrosis. Spinal cord injuries, particularly high cervical lesions, impair both afferent temperature sensing and efferent responses like shivering and vasomotor control. Focal lesions of the hypothalamus or brainstem, demyelinating disease, autoimmune encephalitis and neurodegenerative conditions such as Parkinson’s disease can all disrupt central temperature control, and episodic hypothermia has been documented in migraine, HIV, Parkinson disease and multiple sclerosis.

The authors argue that a central thermoregulatory disorder should be suspected whenever a patient presents with unexplained hypothermia or hyperthermia, particularly without environmental triggers, infection, endocrinopathy or organ failure. It remains largely a diagnosis of exclusion. Additional neurological signs such as autonomic dysfunction or altered mental status may point toward a central cause, though they can also result directly from the thermal derangement itself. Structural brain imaging is paramount in such cases, precisely because the decisive clue in this patient, callosal dysgenesis with a cavum veli interpositi, was present on an earlier scan but initially overlooked. The case is a striking reminder that radiological findings can hide in plain sight until the clinical pattern demands a second look.

Why the corpus callosum matters in Shapiro syndrome is still unresolved, and dysgenesis alone is clearly insufficient to cause the disorder. Hypothalamic involvement is supported by findings of hypothalamic neuronal loss in some reported cases, although structural imaging is often normal. Shapiro’s original hypothesis of diencephalic epilepsy has not held up: patients rarely show EEG abnormalities and generally do not respond to anticonvulsants. Alternative mechanisms, including neurotransmitter dysfunction and hypermelatoninemia, have been proposed, but the cause-and-effect relationship is difficult to disentangle. Some support for the neurotransmitter hypothesis comes from occasional responses to prophylactic agents such as clonidine, clomipramine and cyproheptadine. The patient in this report briefly received clonidine, but treatment was not continued because of poor response, non-compliance and episodes of hypotension, underscoring how difficult management can be in a condition whose mechanisms remain obscure.

The broader lesson from this case extends beyond one rare syndrome. Virtually any neurological disease affecting cognition, sensation or movement can increase susceptibility to thermal dysregulation, but periodic hypothermia and hyperthermia should prompt consideration of a central disorder once infection and systemic disease have been excluded. Diagnostic precision matters because treatment strategies, both pharmacological and non-pharmacological, differ according to the underlying cause, and misattributing recurrent hypothermia to infection leads to repeated courses of unnecessary antimicrobials, as happened here before the true diagnosis emerged. For a man whose body temperature repeatedly fell to levels that would kill most people within hours, the answer lay not in his blood but in a structure of his brain that no one had looked at carefully enough, until a decade of mysterious admissions finally forced a second reading of the scan.

Subject of Research: Shapiro syndrome, a rare disorder of central thermoregulation associated with agenesis of the corpus callosum

Article Title: Recurrent Hypothermia and Autonomic Dysfunction Secondary to Shapiro Syndrome

Article References: Kumar, N., Johnson, J., Watkins, S., & Mulroy, E. (2026). Recurrent Hypothermia and Autonomic Dysfunction Secondary to Shapiro Syndrome. Annals of Clinical and Translational Neurology, 13(8), 1719-1725. https://doi.org/10.1002/acn3.70419

Image Credits: AI Generated

DOI: 10.1002/acn3.70419

Keywords: Shapiro syndrome, hypothermia, corpus callosum, hypothalamus, thermoregulation, autonomic dysfunction, hyperhidrosis, hyponatremia, neurology, case report, episodic spontaneous hypothermia, diencephalon